Push Health Review
Best for: brand-name GLP-1 distribution via large pharmacy network (pending verification)
Push Health is a large US telehealth platform that routes brand-name GLP-1 prescriptions (Ozempic, Zepbound, Mounjaro) through a 55,000+ pharmacy network. LegitScript certified.
Medium confidence · Last verified 2026-04-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Push Health is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Preliminary | brand | $950 |
✓ Pros
- •Brand-name-only GLP-1 distribution (Ozempic, Zepbound, Mounjaro)
- •55,000+ pharmacy network per competitor sources
- •LegitScript certified per competitor sources
- •Listed in both competitor directories
✗ Cons
- •Brand-name-only — no compounded option
- •Stub entry — exact pricing, insurance coordination, and clinician workflow need YMYL verification
- •Confidence LOW until verified
Ready to start with Push Health?
Starting at $950/month. See current pricing and start your free consultation.
Sources & methodology
Our Push Health review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to Push Health
Editorial score · methodology
Editorial score · methodology
Alloy
Best for: women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory
Editorial score · methodology
Frequently Asked Questions
Ready to start with Push Health?
Starting at $950/month. See current pricing and start your free consultation.